Takeaways: Rhapsido gives Canadian clinicians a first-in-class, oral BTK inhibitor option for CSU patients who are still symptomatic on H1 antihistamines, adding a targeted,...
Takeaways Skyhawk’s global Phase 2/3 FALCON-HD program for SKY-0515 positions the company as a front-runner in disease‑modifying treatment for Huntington’s disease, and if successful, a once‑dai...
